Table 2.
Demographics and basic characteristics of patients, together with radiological and electrocardiographic results
| All patients (n = 40) |
No ICU admission (n = 27) |
ICU admission (n = 13) |
p-Value | |
|---|---|---|---|---|
| Clinical manifestations | ||||
| Age (years) | 67 ± 17 | 66 ± 19 | 69 ± 15 | 0.7 |
| Female gender, n (%) | 15 (37.5) | 14 (51.9) | 1 (7.7) | 0.013 |
| Hypertension, n (%) | 19 (47.5) | 14 (51.9) | 5 (38.5) | 0.511 |
| Diabetes, n (%) | 11 (27.5) | 4 (14. 8) | 7 (53.8) | 0.02 |
| History of cardiac disease, n (%) | 10 (25) | 0 (0) | 10 (25) | 0.016 |
| Family history of cardiac disease, n (%) | 4 (10) | 0 (0) | 4 (14.8) | 0.28 |
| Temperature, °C | 38.4 ± 1.6 | 38.5 ± 1.3 | 38.4 ± 1.5 | 0.73 |
| O2 (%) | 89 ± 5 | 91 ± 2 | 84 ± 7 | 0.001 |
| Catecholamine therapy, n (%) | 7 (17.5) | 0 (0) | 7 (53.8) | <0.01 |
| Mechanical ventilation, n (%) | 9 (22) | 0 (0) | 9 (60) | <0.01 |
| Mortality, n (%) | 8 (20) | 4 (14.8) | 4 (30.8) | 0.4 |
| Duration of hospital stay (days) | 14 ± 9 | 9 ± 6 | 21 ± 8 | <0.01 |
| Clinical symptoms | ||||
| Fever, n (%) | 25 (62.5) | 15 (55.6) | 10 (76.9) | 0.17 |
| Dyspnea, n (%) | 20 (50) | 12 (44.4) | 8 (61.5) | 0.5 |
| Sore throat, n (%) | 12 (30) | 6 (22.2) | 6 (46.2) | – |
| Chest pain, n (%) | 11 (52.5) | 7 (25.9) | 4 (30. 8) | 0.51 |
| Cough, n (%) | 17 (42.5) | 9 (33.3) | 8 (61.5 ) | 0.17 |
| CT staging (n = 40) | ||||
| CO-RADS 3, n (%) | 16 (40) | 16 (59.3) | 0 (0) | 0.001 |
| CO-RADS 4, n (%) | 10 (25) | 4 (14.8) | 6 (46.2) | |
| CO-RADS 5, n (%) | 14 (35) | 7 (25.9) | 7 (53.8) | |
| Laboratory findings | ||||
| CRP (mg/l) | 87.4 ± 61.6 | 58.6 ± 42.5 | 142.8 ± 55.2 | <0.01 |
| Leucocyte count (10e3/µl) | 7.9 ± 3.3 | 7.7 ± 3.9 | 8.1 ± 1.4 | 0.71 |
| Lymphocytes (10e3/µl) | 1.7 ± 1.8 | 2.1 ± 2.1 | 1 ± 0.5 | 0.06 |
| Thrombocytes (10e3/µl) | 299.9 ± 169.6 | 305.1 ± 168.5 | 289.2 ± 178.2 | 0.8 |
| Procalcitonin (µg/l) | 0.53 ± 0.98 | 0.49 ± 1.1 | 0.6 ± 0.67 | 0.7 |
| CK (U/l) |
242.9 ± 254.3 (median 125.5) |
143.8 ± 162.1 | 408.2 ± 297.2 | 0.001 |
| CKMB (U/l) | 24 ± 14.9 | 20.5 ± 8.9 | 31.2 ± 21.7 | <0.05 |
| Troponin (pg/ml) | 27.7 ± 20.7 | 20.8 ± 17.5 | 39.3 ± 21 | 0.005 |
| NT-ProBNP (pg/ml) |
1847.5 ± 2582.9 (median 682.5) |
738.4 ± 842.8 (median 590.0) |
3695.9 ± 3392.8 | <0.01 |
| D‑dimer (mg/l) |
2.3 ± 3.8 (median 1.09) |
1.6 ± 1.7 | 3.8 ± 6.0 | 0.08 |
| FLC Ig lambda (mg/l) | 45.6 ± 41.1 | 33.9 ± 16.6 | 69.9 ± 62.9 | 0.008 |
| FLC Ig kappa (mg/l) | 38.5 ± 23.7 | 31.2 ± 10.0 | 53.7 ± 34.8 | 0.003 |
| Ferritin (ng/ml) |
855.78 ± 1332.4 (median 601.00) |
619.3 ± 428.8 |
1345.6 ± 2233 (median 596.00) |
0.1 |
| ALT (U/l) | 63.9 ± 52.9 | 56.7 ± 39.8 | 78.8 ± 73 | 0.24 |
| Creatinine (mg/dl) | 0.8 ± 0.2 | 0.73 ± 0.15 | 0.89 ± 0.23 | 0.02 |
| Electrocardiographic parameters | ||||
| Diffuse ST-segment elevation, n (%) | 2 (5) | 1 (4) | 1 (6.7) | 1 |
| Prolonged PR time, n (%) | 8 (20) | 4 (16) | 4 (26.7) | 0.44 |
| PR time (ms) | 181 ± 25 | 180 ± 25 | 182 ± 26 | 0.34 |
| Prolonged QTc time, n (%) | 2 (5) | 0 (0) | 2 (13.3) | 0.14 |
| QTc time (ms) | 436 ± 31 | 434 ± 32 | 438 ± 28 | 0.43 |
| Right bundle branch block, n (%) | 2 (5) | 0 (0) | 2 (13.3) | 0.13 |
| Left bundle branch block, n (%) | 1 (2.5) | 1 (4) | 0 (0) | 1 |
| New-onset atrial fibrillation, n (%) | 2 (5) | 1 (4) | 1 (6.7) | 1 |
O2 oxygen saturation, CO-RADS COVID-19 Reporting and Data System, CRP C-reactive protein, CK creatine kinase, CKMB creatine kinase mb-fraction, NT-ProBNP N-terminal pro brain natriuretic peptide, FLC Ig free light chain immunoglobulin, ALT alanine aminotransferase, IL6 interleukin 6, SD standard deviation